Samil Pharmaceutical Co.,Ltd

KOSE:A000520 Stok Raporu

Piyasa değeri: ₩343.8b

Samil PharmaceuticalLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Samil PharmaceuticalLtd has been growing earnings at an average annual rate of 3%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 13.8% per year.

Anahtar bilgiler

3.0%

Kazanç büyüme oranı

3.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi11.3%
Gelir büyüme oranı13.8%
Özkaynak getirisi-0.7%
Net Marj-0.5%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Recent updates

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

Sep 13
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Sep 11
We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Jul 29
Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

May 24
Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30
There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15
Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24
Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18
What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Gelir ve Gider Dağılımı

Samil PharmaceuticalLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

KOSE:A000520 Gelir, gider ve kazançlar (KRW Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24210,733-1,15564,5325,913
31 Mar 24204,905-78661,4615,870
31 Dec 23196,3461,66459,9625,601
30 Sep 23189,2932,60059,6385,249
30 Jun 23183,0601,33659,7524,342
31 Mar 23179,56634358,9073,553
31 Dec 22179,676-2858,5192,907
30 Sep 22170,510-4,98955,3642,359
30 Jun 22158,910-4,74051,2262,617
31 Mar 22147,877-5,61948,0472,948
31 Dec 21134,247-5,34743,7632,971
30 Sep 21129,974-2,76141,6343,007
30 Jun 21127,287-1,32740,7093,007
31 Mar 21122,79313238,9602,593
31 Dec 20122,9991,34137,9893,007
30 Sep 20123,11494036,5103,185
30 Jun 20122,30872937,0872,847
31 Mar 20123,1021,42937,4613,183
31 Dec 19121,10778637,4533,060
30 Sep 19114,364-1,25137,7923,060
30 Jun 19107,856-3,36837,0172,969
31 Mar 19102,805-6,46137,4982,619
31 Dec 1894,600-8,56337,3732,182
30 Sep 1896,882-5,16537,5802,026
30 Jun 1894,916-4,60536,9252,087
31 Mar 1892,286-2,79736,1681,987
31 Dec 1792,038-1,26736,7341,961
30 Sep 1790,658-1,43435,7921,938
30 Jun 1792,11889835,3571,605
31 Mar 1794,68594835,8821,447
31 Dec 1696,75888735,6671,254
30 Sep 1694,01030635,3091,047
30 Jun 1692,62514034,9091,136
31 Mar 1688,65655333,5031,121
31 Dec 1588,13658833,6881,119
30 Sep 1585,795-2,98635,2501,457
30 Jun 1585,439-6,17036,9031,831
31 Mar 1585,849-10,17939,2252,477
31 Dec 1485,461-11,19039,0112,790
30 Sep 1487,6831,14837,9982,841
30 Jun 1487,5453,60137,0612,126
31 Mar 1489,2077,19134,5622,182
31 Dec 1389,2297,93034,6312,046

Kaliteli Kazançlar: A000520 is currently unprofitable.

Büyüyen Kar Marjı: A000520 is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A000520 is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Büyüme Hızlandırma: Unable to compare A000520's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: A000520 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).

Özkaynak Getirisi

Yüksek ROE: A000520 has a negative Return on Equity (-0.66%), as it is currently unprofitable.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y